Life-threatening risks associated with HLA-mismatched unrelated donor hematopoietic cell transplantation (HCT) limit its general application for the treatment of blood diseases. In CA100019, we have taken a haplotype approach to investigate the MHC as a source of untyped variation. We mapped haplotype effects of acute or chronic graft-versus-host disease (GVHD), relapse, or mortality after HLA-mismatched unrelated donor HCT to 12 single nucleotide polymorphisms (SNPs). SNP-associated risks were conferred by either patient or donor genotype or by patient-donor mismatching. Risks after transplantation increased with increasing numbers of unfavorable SNPs. SNPs affected acute GVHD independently from chronic GVHD. SNPs also lowered relapse independently of GVHD. Haplotype-specific content for candidate genes can be used clinically to assess risks in patients and to select donors with optimal MHC genetics.
The aims of CA100019 are to: 1) confirm the impact of the 12 SNPs in HLA-mismatched transplants;2) determine the content of homozygous HLA haplotypes for candidate transplant genes;3) identify specific polymorphisms associated with risks after mismatched unrelated HCT, and 4) identify risks associated with HLA mismatches. CA100019 will contribute novel information on the genes and putative pathways involved in GVHD and graft- versus-leukemia, and provide clinicians with a haplotype-based approach for optimizing HLA-mismatched unrelated donor HCT.

Public Health Relevance

We are discovering the genes that are responsible for the success of blood and marrow transplantation from unrelated donors. Information on these genes will help physicians to choose better donors and to lower risks for patients who need a transplant to cure diseases of the blood system.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Merritt, William D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Schöne, Bianca; Bergmann, Sabine; Lang, Kathrin et al. (2018) Predicting an HLA-DPB1 expression marker based on standard DPB1 genotyping: Linkage analysis of over 32,000 samples. Hum Immunol 79:20-27
El-Jawahri, Areej; LeBlanc, Thomas W; Burns, Linda J et al. (2018) What do transplant physicians think about palliative care? A national survey study. Cancer 124:4556-4566
Petersdorf, Effie W; O'hUigin, Colm (2018) The MHC in the Era of Next-Generation Sequencing: Implications for Bridging Structure with Function. Hum Immunol :
Petersdorf, Effie W (2017) Which factors influence the development of GVHD in HLA-matched or mismatched transplants? Best Pract Res Clin Haematol 30:333-335
Petersdorf, E W (2017) In celebration of Ruggero Ceppellini: HLA in transplantation. HLA 89:71-76
Petersdorf, Effie W (2016) Mismatched unrelated donor transplantation. Semin Hematol 53:230-236
Boyiadzis, Michael; Arora, Mukta; Klein, John P et al. (2015) Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res 21:2020-8
Petersdorf, Effie W; Malkki, Mari; O'hUigin, Colm et al. (2015) High HLA-DP Expression and Graft-versus-Host Disease. N Engl J Med 373:599-609
Petersdorf, Effie W (2015) HLA mismatching in transplantation. Blood 125:1058-9

Showing the most recent 10 out of 37 publications